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Neurotransmitters released from sympathetic and parasympathetic nerve terminals in the
sinoatrial node (SAN) exert their effects via G-protein-coupled receptors. Integration of
these different G-protein signals within pacemaker cells of the SAN is critical for proper
regulation of heart rate and function. For example, excessive parasympathetic signaling
can be associated with sinus node dysfunction (SND) and supraventricular arrhythmias.
Our previous work has shown that one member of the regulator of G-protein signaling
(RGS) protein family, RGS4, is highly and selectively expressed in pacemaker cells of the
SAN. Consistent with its role as an inhibitor of parasympathetic signaling, RGS4-knockout
mice have reduced basal heart rates and enhanced negative chronotropic responses to
parasympathetic agonists. Moreover, RGS4 appears to be an important part of SA nodal
myocyte signaling pathways that mediate G-protein-coupled inwardly rectifying potassium
channel (GIRK) channel activation/deactivation and desensitization. Since RGS4 acts imme-
diately downstream of M2 muscarinic receptors, it is tempting to speculate that RGS4
functions as a master regulator of parasympathetic signaling upstream of GIRKs, HCNs,
and L -type Ca2+ channels in the SAN.Thus, loss of RGS4 function may lead to increased
susceptibility to conditions associated with increased parasympathetic signaling, including
bradyarrhythmia, SND, and atrial ﬁbrillation.
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SINUS NODE DYSFUNCTION
Sinus node dysfunction (SND) can be associated with brady-
cardia/bradyarrhythmias, sinus node exit block, and increased
susceptibility to atrial ﬁbrillation (Benditt et al., 1995; Man-
grum and DiMarco, 2000; Dobrzynski et al., 2007). This con-
dition, also known as sick sinus syndrome, occurs commonly
within the aging adult population, but is particularly preva-
lent in patients with heart disease, on anti-arrhythmic therapy,
with high vagal tone, or after surgical correction of congeni-
tal heart defects. Genetic predisposition for SND has also been
proposed in patients and that have this condition in conjunc-
tion with abnormal ion channel and GTPase activating protein
(GAP) junction function (Bezzina et al., 1999; Benson et al.,
2003; Groenewegen et al., 2003; Schulze-Bahr et al., 2003; Veld-
kamp et al., 2003; Ueda et al., 2004; Mohler and Bennett, 2005;
Smits et al., 2005; Milanesi et al., 2006). Thus in order to
treat and prevent SND, it may be important to understand the
cast of molecules that coordinate the balance between auto-
nomic signaling pathways within pacemaker cells of the sinoatrial
node (SAN).
G-PROTEIN-COUPLED RECEPTORS MEDIATED AUTONOMIC
CONTROL OF HEART RATE IN THE SAN
Heart rate regulation by the autonomic nervous system occurs
at the level of specialized autorhythmic (pacemaker) cells in
the SAN. Sympathetic neurotransmitters work via Gαs-coupled
β-adrenergic receptors (β-ARs) to increase adenylyl cyclase
activity, intracellular cAMP concentration, and protein kinase
A (PKA) activity. As a result cAMP-regulated effectors such
as hyperpolarization-activated cyclic nucleotide-gated cation
(HCN), delayed rectiﬁer, and voltage-gated Ca2+ channels are
enlisted by sympathetic activity to increase pacemaker cell ﬁr-
ing rat (Irisawa et al., 1993; DiFrancesco, 2006). By contrast,
vagal parasympathetic activity decreases HR via Gαi/o-coupled
cholinergic M2 muscarinic receptors (M2 muscarinic recep-
tor). Several effects, mediated by both Gαi/o and Gβγ sub-
units contribute to this reduction in HR. Gβγ heterodimers
directly activate G-protein-coupled inward rectifying potassium
(GIRK)channels,resultinginmembranehyperpolarization.Gαi/o
can also inhibit adenylyl cyclase activity to reduce intracellu-
lar cAMP levels and PKA activity, thus leading to decreased
depolarizing currents carried by HCN and L-type Ca2+ chan-
nels (DiFrancesco, 1993; Kubo et al., 1993; Fischmeister et al.,
2006). Since dysregulation of parasympathetic activity occurs
in SND and selected cardiac arrhythmias (Dobrzynski et al.,
2007), it is of clinical interest to identify key molecular regula-
tors of parasympathetic signaling. In particular, our laboratory
studies molecules that regulate the activity of G-protein sig-
naling downstream of parasympathetic activation inside SAN
cells.
RGS PROTEINS ATTENUATE G-PROTEIN SIGNALING IN THE
SAN
The activation of the Gαi/o-coupled M2 muscarinic receptor by
cholinergic(parasympathetic)activityproducesacascadeofphys-
iologic changes within the cell. The timing and duration of these
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changes are mainly dependent on the lifetime of the activated
(GTP-bound) Gαi/o subunit. In the basal state, the quiescent
(GDP-bound) Gαi/o subunit is complexed with the Gβγ and cou-
pled to the intracellular surface of the receptor. Speciﬁcally, M2
muscarinic receptor activation results in the exchange of GTP
for GDP on the Gα subunit and the dissociation of GTP-bound
Gα from the Gβγ heterodimer. This condition marks the acti-
vated (“ON”) state (Clapham and Neer, 1997; Hamm, 1998)o f
parasympathetic signaling during which time the Gα and Gβγ
subunits are free to engage downstream parasympathetic effector
molecules such as GIRK channels and adenylyl cyclase. Effec-
tor signaling is terminated following Gα-catalyzed hydrolysis of
GTP and reformation of the quiescent (“OFF”) receptor-coupled
complex. Importantly, the intrinsic rate of GTP hydrolysis by Gα
subunits (the rate limiting step for signal termination) is very
slow. Therefore, to produce the rapid ON-OFF kinetic changes
needed to modulate autonomic activity in vivo cells require addi-
tional factors that increase the rate of GTP hydrolysis of the
Gα subunit. This class of molecules is called GAPs. Regulator
of G-protein signaling (RGS) proteins (Hepler, 1999; Ross and
Wilkie, 2000) are a mammalian family of >35 GAPs for Gα sub-
units (Berman et al., 1996; Watson et al., 1996). By increasing
the rates of GTP hydrolysis by up to 2000-fold RGS proteins are
amongthemostpotentinhibitorsofG-proteinsignalingidentiﬁed
to date.
Endogenous RGS proteins have recently been shown to play an
important role in the regulation of muscarinic receptor-mediated
signaling.Inembryonicstemcell-derivedcardiomyocytes,expres-
sionof RGS-insensitiveGαi2 andGαo subunitsenhancedsensitiv-
ity of these cells to the M2 muscarinic and adenosine receptor
agonists (Fu et al., 2006). Similar observations were also shown
in the intact animal and isolated perfused hearts (Fu et al., 2006,
2007). Despite M2R and adenosine receptor (A1R) both mediat-
ing negative chronotropic effects, it appears that these receptors
may do so through distinct intracellular mechanisms. Speciﬁcally,
the M2R appears to signal via Gαi2 and Gαo, whereas the adeno-
sine receptor appears to signal predominantly via Gαo. It may not
besurprising,therefore,thatthecontributionof GIRKcurrentsto
M2R- versus A1R-mediated heart rate slowing effects appears to
be different. Tertiapin-Q abolished the increased responsiveness
of RGS-resistant Gαi2 tissues to carbachol suggesting the impor-
tance of GIRK activity as a primary pathway mediating the M2R
chronotropicresponseandestablishingaroleforendogenousRGS
proteins as inhibitors of this pathway. By contrast, the enhanced
sensitivity of RGS-resistant Gαo cells to A1R agonist is unaffected
by tertiapin-Q, suggesting minimal contribution of GIRK activa-
tion to the heart rate slowing effects of A1R agonists. Since, as
outlined above,A1R preferentially couple to Gαo it has been sug-
gested that A1R are likely to use a GIRK-independent pathway
(e.g., ICa,L or If) to mediate its bradycardic effects. These excit-
ing observations prompted the search for RGS proteins that may
selectivelyregulatetheactivityof Gαi2 andGαo ortheirassociated
receptors in pacemaker cells of the SAN. A number of differ-
ent RGS proteins have been identiﬁed in the atrial myocardium
(Kardestunceretal.,1998;Doupniketal.,2001);however,thespe-
ciﬁc RGS protein responsible for this effect was not characterized
in these studies.
RGS4 IS WELL-SUITED TO ATTENUATE PARASYMPATHETIC
SIGNALING
Regulator of G-protein signaling 4 was one of the ﬁrst pro-
teins of this superfamily to be cloned and characterized (Berman
et al., 1996; Druey et al., 1996; Watson et al., 1996). Of the
main G-protein signaling pathways controlling heart rate, RGS4
shows a remarkable degree of biochemical selectivity for inhibit-
ingGαi/o relativ etoGαs function.RGS4hasbeenshowntoinhibit
neural (Pacey et al., 2009), pancreatic (Ruiz de Azua et al., 2010),
tumor (Xie et al., 2009), and cardiac cell signaling (Zhang et al.,
1998; Mittmann et al., 2002). Overexpression of RGS4 can also
prevent hypertrophic growth in cardiomyocytes (Rogers et al.,
1999, 2001; Tamirisa et al., 1999; Tokudome et al., 2008). Sev-
eral papers from Doupnik and colleagues have demonstrated the
potential importance of RGS4 as an inhibitor of hyperpolariz-
ing GIRK channels (Doupnik et al., 1997, 2004; Zhang et al.,
2002, 2004). Importantly, RGS4 has been shown to selectively
associate with the M2 muscarinic receptor and GIRK channels
in pulldown experiments (Jaen and Doupnik, 2006). Moreover,
because of its biochemical selectivity for inhibiting Gαi/o- but
not Gαs-signaling (Berman et al., 1996), RGS4 is well-positioned
to regulate parasympathetic signaling without directly affecting
sympatheticallyderivedsignalsatthelevelof thereceptor.Accord-
ingly,throughitsabilitytomodulateGαi/o-mediatedregulationof
GIRK channel activation,RGS4 was predicted to be an important
inhibitor of the negative chronotropic actions of parasympathetic
activity.
RGS PROTEINS INHIBIT PARASYMPATHETIC SIGNALING IN
PACEMAKER CELLS OF THE SAN
Using a RGS4-knockout mouse strain with a LacZ reporter cas-
sette, our laboratory showed that RGS4 is highly and selectively
expressed in the SAN compared to other regions of the heart
(Cifellietal.,2008).ItshighrelativeexpressionintheSANwasevi-
dent from whole-mount LacZ staining of intact hearts and right
atrial preparations as well as from correlation of LacZ patterns
with HCN4 immunolabeling. Consistent with an important role
for RGS4 as an inhibitor of parasympathetic signaling in the SAN,
RGS4-null mice show increased bradycardic responses to carba-
chol (parasympathetic agonist mimetic) in waking animals and
lower baseline heart rates in anesthetized models. Retrograde-
perfused hearts from RGS4-null mice show enhanced negative
chronotropic responses to carbachol, while isolated pacemaker
cells of the SAN show greater sensitivity to carbachol-mediated
reduction in the action potential ﬁring rate. Moreover, RGS4-
null SAN cells show decreased levels of G-protein-coupled inward
rectifying potassium (GIRK) channel desensitization (i.e., greater
channel activity with prolonged stimulus), and altered modula-
tion of GIRK channel current (IKACh) kinetics following both
carbachol addition and removal. In particular, the IKACh persists
much longer after carbachol washout in the RGS4-null com-
pared to wild type cells, consistent with the loss of a key kinetic
inhibitor of Gαi/o signaling. Lastly, RGS4-null pacemaker cells
of the SAN treated with carbachol showed marked membrane
hyperpolarization and loss of spontaneous action potential activ-
ity, reminiscent of the loss in SA node automaticity observed in
patientswithSND.Figure1summarizesthepotentialroleofRGS4
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FIGURE 1 | Modeling parasympathetic signaling pathways in
pacemaker cells of the SAN in the presence (A) and absence (B) of
RGS4 function. Note the potential for RGS4 to act as a master upstream
regulator of the primary effectors of the M2 muscarinic receptor (GIRK
channels, and adenylyl cyclase). (A) In the model where RGS4 is functional,
Gαi signaling is attenuated resulting in decreased GIRK channel activity and
increased cAMP concentrations that can directly stimulate increased HCN4
channel activity and indirectly (via PKA activation) increases CaV channel
activity. (B) In the model where RGS4 function is absent Gαi signaling is
increased resulting in increased GIRK channel activity and decreased cAMP
concentrations.This condition is expected to result in lower HCN4 and CaV
channel activity.
as a master regulator of parasympathetic signaling downstream
of the M2 muscarinic receptor. As summarized by the compar-
ison of M2 muscarinic receptor-dependent signaling events in
Figures 1A,B, the loss of RGS4 function in pacemaker cells of
the SAN may be expected to result in increased GIRK channel
currents, decreased adenylyl cyclase activity/cAMP production,
leading to decreased activation of HCN4, protein kinase A, and
L-typecalciumchannelcurrents.Asdiscussedabove,lossof RGS4
is known to increase M2 muscarinic receptor-dependent GIRK
currents, however the question of whether HCN4 and L-type cal-
ciumchannelcurrentsareaffectedinanymeaningfulwayremains
to be determined.
More recently, RGS6 was also shown to be an important
regulator of M2R-dependent signaling in the SAN. Speciﬁcally,
two groups working independently showed that RGS6-deﬁcient
mice, displayed enhanced bradycardic responses to carbachol in
intactanimals,isolatedhearts,andculturedSANcells(Posokhova
et al., 2010; Yang et al., 2010). As was the case for RGS4-
deﬁciency, the phenotypes associated with loss of RGS6 appeared
consistent with its ability to regulate GIRK channel activity. It
remains to be determined whether RGS6 will also be capable
of regulating GIRK channel independent effectors of negative
chronotropy.
HEART-INTRINSIC REGULATION OF VAGAL SIGNALING – A
POSSIBLE ROLE FOR RGS PROTEINS?
Itisinterestingtoconsiderwhethertheremayexistheart-intrinsic
mechanisms that would allow for rapid changes in RGS protein
activity, and thus rapid changes in heart rate and cardiac output
in response to certain physiologic stimuli. One stimulus that is
believed to regulate heart rate at the level of the SAN is atrial
stretch. This pathway has been proposed to be one of the intrinsic
mechanisms whereby increased venous return may result in rapid
upregulation of cardiac output via alterations of the autonomic
signaling balance. Speciﬁcally, small increases in atrial pressure
have been shown to reduce the heart’s response to vagal stimu-
lation resulting in rapid heart rate increase (Bolter and Wilson,
1999). Of potential relevance to this article is the observation
that the increased heart rate effect is apparently mediated by
rapid inhibition of GIRK channel activity in response to atrial
stretch. Indeed,it was shown that Tertiapin-Q could eliminate the
mechanosensitive component of muscarinic control in rat atria
(Han et al., 2010). Although the cellular mechanisms by which
stretch is sensed and exerts its effects on the SAN are not known it
istemptingtospeculatethattherapidregulationofGIRKchannels
in response to changing atrial pressures may be partly explained
by changes in RGS protein activity. While, there are wide num-
ber of pathways that have been proposed to regulate the function
of RGS4, an intriguing possibility for linking mechanosensation
to increased RGS4 function is the Ca2+/Calmodulin pathway.
Mechanical stretch has been associated with increased intracel-
lular calcium levels in atrial tissues, and rapid activation of RGS4
activity was shown to be associated with Ca2+/calmodulin bind-
ing to an allosteric site on the RGS4 protein (Popov et al., 2000;
Ishii et al., 2001, 2002). Thus, atrial stretch might be expected to
increaseRGS4activity,resultingindecreasedparasympatheticsig-
nals and heart rate increase. It remains to be determined whether
other RGS proteins important for regulation of GIRKs in the
SAN (i.e., RGS6) may also be regulated by mechanosensitive
pathways.
INCREASED IKAch MAY BE PRO-ARRHYTHMOGENIC – DOES
LOSS OF RGS PROTEIN EXPRESSION RENDER HEARTS MORE
SUSCEPTIBLE?
In animal models of AF, stimulation with the muscarinic ago-
nist carbachol can facilitate the induction of AF (Wakimoto et al.,
2001), whereas inhibition of Gi/o signaling can reduce suscepti-
bility to vagal-mediated AF (Aistrup et al., 2009, 2011). In the
clinic, Coumel (1996) have described cases of AF where vagal
activity preceded the onset of atrial arrhythmias (Herweg et al.,
1998). Several observations suggest that activation of IKAch may
beakeycomponentof parasympatheticpathway-mediatedinitia-
tion and maintenance of AF. Firstly, studies show that reducing
IKAch using both genetic disruption (Kovoor et al., 2001) and
pharmacological inhibition (Hashimoto et al., 2006) of GIRK
currents confers resistance to AF, while increasing IKAch facili-
tates induction of AF (Kovoor et al., 2001). Furthermore, Voigt
et al. (2008) demonstrated the presence of agonist-independent
IKAch activity in a canine model of chronic AF. Importantly, evi-
dence from human studies conﬁrms the presence of constitutively
active (agonist-independent) IKAch in patients with persistent AF
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(Dobrev et al., 2005). Human studies identiﬁed a genetic poly-
morphism in the β3 subunit of heterotrimeric G-proteins which
was associated with reduced IKAch in human atrial myocytes
(Dobrevetal.,2000)andprotectionfromAFinhumans(Schreieck
et al., 2004). These ﬁndings suggest that a reduction of IKAch
could be beneﬁcial in AF prevention and treatment and makes
endogenous inhibitors of IKAch, such as RGS4, potentially inter-
esting anti-arrhythmic targets. Indeed, much work in the area
of pharmacologic targeting of RGS proteins in cardiovascular
and other tissues has already been carried out. Several of the
key discoveries in this ﬁeld are discussed elsewhere in a com-
prehensive series of recent reviews on this topic (Sjogren and
Neubig,2010;Sjogrenetal.,2010;Kimpleetal.,2011;Zhangetal.,
2012).
Thus, two important aspects of the phenotype observed in
RGS4-deﬁcient hearts suggest that they may be expected to
show increased susceptibility to AF. First, the characteristic brad-
yarrhythmiathatwasfoundtobeassociatedwithvagalstimulation
may signiﬁcantly increase the chance that an ectopic pacemaker
could act to trigger an arrhythmia (Schuessler et al., 1992; Chou
et al., 2008). Second, to the extent that RGS4 is required for inhi-
bition of parasympathetic signaling in the atrial syncytium, loss
of RGS4 may predispose hearts to regional changes in repolariza-
tionkineticsthatmightsupportre-entrantcircuitsinthepresence
of M2 muscarinic receptor activation. Speciﬁcally, the increased
GIRK channel activity that is characteristic of RGS4-deﬁcient
hearts may be expected to contribute to a decrease in the action
potential duration of atrial myocytes and thus lead to increased
susceptibility to rotor formation. Future studies will be required
to determine whether this is indeed the case. It is currently not
known whether RGS4 expression is decreased in the SAN or atria
of patients with SND or AF, but it would be tempting to exam-
ine these possibilities. Likewise, certain SNPs in the non-coding
regions of the RGS4 gene have been associated with schizophre-
nia in the general population (Chowdari et al.,2002; Morris et al.,
2004) so it would be of interest to determine whether individuals
with those SNPs may also show increased susceptibility to SAN
dysfunction and supraventricular arrhythmias.
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